Filing Details
- Accession Number:
- 0001209191-20-007485
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-02-07 16:14:19
- Reporting Period:
- 2020-02-05
- Accepted Time:
- 2020-02-07 16:14:19
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1735944 | Reshma Kewalramani | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Evp And Cmo | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2020-02-05 | 9,800 | $0.00 | 22,898 | No | 4 | A | Direct | |
Common Stock | Acquisiton | 2020-02-05 | 12,387 | $0.00 | 35,285 | No | 4 | A | Direct | |
Common Stock | Disposition | 2020-02-06 | 1,564 | $187.53 | 36,849 | No | 4 | M | Direct | |
Common Stock | Disposition | 2020-02-06 | 510 | $155.57 | 37,359 | No | 4 | M | Direct | |
Common Stock | Disposition | 2020-02-06 | 1,251 | $238.76 | 36,108 | No | 4 | S | Direct | |
Common Stock | Disposition | 2020-02-06 | 423 | $239.69 | 35,685 | No | 4 | S | Direct | |
Common Stock | Disposition | 2020-02-06 | 271 | $240.75 | 35,414 | No | 4 | S | Direct | |
Common Stock | Disposition | 2020-02-06 | 129 | $242.47 | 35,285 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | A | Direct | |
No | 4 | A | Direct | |
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2020-02-06 | 1,564 | $0.00 | 1,564 | $187.53 |
Common Stock | Stock Option (Right to Buy) | Disposition | 2020-02-06 | 510 | $0.00 | 510 | $155.57 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
18,770 | 2029-02-05 | No | 4 | M | Direct | |
4,077 | 2028-02-05 | No | 4 | M | Direct |
Footnotes
- Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/05/2020. The earned performance shares will vest in installments beginning on 2/24/2020.
- Restricted stock unit award that vests in installments beginning on 02/10/2021.
- Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of $238.76 (range $238.15 to $239.11).
- Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $239.69 (range $239.20 to $240.19).
- Open market sales reported on this line occurred at a weighted average price of $240.75 (range $240.40 to $241.12).
- The option vests in 16 quarterly installments from 02/06/2019.
- The option vests in 16 quarterly installments from 02/06/2018.